Search

Your search keyword '"Bodiyabadu, Kaveesha"' showing total 21 results
Start Over Author "Bodiyabadu, Kaveesha"
21 results on '"Bodiyabadu, Kaveesha"'

1. Doxycycline and Sitafloxacin Combination Therapy for Treating Highly Resistant Mycoplasma genitalium

Author

Durukan, Duygu, Doyle, Michelle, Murray, Gerald, Bodiyabadu, Kaveesha, Vodstrcil, Lenka, Chow, Eric P.F., Jensen, Jorgen S., Fairley, Christopher K., Aguirre, Ivette, and Bradshaw, Catriona S.

Subjects
Sexually transmitted diseases -- Care and treatment, Doxycycline -- Health aspects, Microbial drug resistance -- Care and treatment, Infection -- Care and treatment, Health
Abstract

Mycoplasma genitalium is a sexually transmitted bacterium with marked capacity for developing antimicrobial resistance (1). Macrolides and 4th-generation fluroquinolones, such as moxifloxacin, have been the main agents displaying efficacy against [...]

Published
2020
Full Text
View/download PDF

4. gyrA Mutations in Mycoplasma Genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-guided Therapy

Author

Murray, Gerald L, primary, Plummer, Erica L, additional, Bodiyabadu, Kaveesha, additional, Vodstrcil, Lenka A, additional, Huaman, Jose L, additional, Danielewski, Jennifer A, additional, Chua, Teck Phui, additional, Machalek, Dorothy A, additional, Garland, Suzanne, additional, Doyle, Michelle, additional, Sweeney, Emma L, additional, Whiley, David M, additional, and Bradshaw, Catriona S, additional

Published
2023
Full Text
View/download PDF

7. Combination Therapy for Mycoplasma genitalium, and New Insights Into the Utility of parC Mutant Detection to Improve Cure

Author

Vodstrcil, Lenka A, primary, Plummer, Erica L, additional, Doyle, Michelle, additional, Murray, Gerald L, additional, Bodiyabadu, Kaveesha, additional, Jensen, Jorgen S, additional, Whiley, David, additional, Sweeney, Emma, additional, Williamson, Deborah A, additional, Chow, Eric P F, additional, Fairley, Christopher K, additional, and Bradshaw, Catriona S, additional

Published
2022
Full Text
View/download PDF

8. Prevalence of Mycoplasma genitalium fluoroquinolone-resistance markers, and dual-class-resistance markers, in asymptomatic men who have sex with men

Author

Chua, Teck-Phui, primary, Bodiyabadu, Kaveesha, additional, Machalek, Dorothy A., additional, Garland, Suzanne M., additional, Bradshaw, Catriona S., additional, Plummer, Erica L., additional, Danielewski, Jennifer, additional, Vodstrcil, Lenka A., additional, Doyle, Michelle L., additional, and Murray, Gerald L., additional

Published
2021
Full Text
View/download PDF

9. The clinical indications for testing women for Mycoplasma genitalium

Author

Latimer, Rosie L, primary, Vodstrcil, Lenka A, additional, Plummer, Erica L, additional, Doyle, Michelle, additional, Murray, Gerald L, additional, Fairley, Christopher K, additional, Bodiyabadu, Kaveesha, additional, Read, Tim R H, additional, Kaiser, Marti, additional, Mokany, Elisa, additional, Guy, Rebecca, additional, Chow, Eric P F, additional, and Bradshaw, Catriona, additional

Published
2021
Full Text
View/download PDF

11. The clinical indications for testing women for .

Author

Latimer, Rosie L., Vodstrcil, Lenka A., Plummer, Erica L., Doyle, Michelle, Murray, Gerald L., Fairley, Christopher K., Bodiyabadu, Kaveesha, Read, Tim R. H., Kaiser, Marti, Mokany, Elisa, Guy, Rebecca, Chow, Eric P. F., and Bradshaw, Catriona

Subjects
ANTIBIOTICS, MYCOPLASMA, RESEARCH, MYCOPLASMA diseases, CROSS-sectional method, RESEARCH methodology, UTERINE cervicitis, EVALUATION research, COMPARATIVE studies, NEISSERIA, DISEASE prevalence, CHLAMYDIA trachomatis, DRUG resistance in microorganisms, CHLAMYDIA infections, MACROLIDE antibiotics
Abstract

Background: While the contribution of Mycoplasma genitalium (MG) to symptoms in men is well described, less is known about its association with common genital symptoms in women. We aimed to determine the prevalence of MG and macrolide resistance, and its association with common genital symptoms in women attending a sexual health service, to inform indications for testing and clinical practice.Methods: We undertook a cross-sectional study of symptomatic and asymptomatic women attending Melbourne Sexual Health Centre (MSHC), between April 2017 and April 2019. Women were tested for MG and macrolide resistance, Chlamydia trachomatis (CT), Neisseria gonorrhoeae, Trichomonas vaginalis, bacterial vaginosis and vulvovaginal candidiasis. Women completed a questionnaire on symptoms, and symptomatic women underwent examination. The prevalence of MG (and macrolide resistance) and other genital infections was calculated with 95% CIs, and associations between these outcomes and specific genital symptoms were examined using logistic regression.Results: Of 1318 women, 83 (6%, 95% CI: 5% to 8%) had MG, of which 39 (48%, 95% CI: 36% to 59%) had macrolide-resistant MG; 103 (8%, 95% CI: 6% to 9%) women had CT. MG prevalence was similar in asymptomatic (10 of 195; 5%) and symptomatic (73 of 1108; 7%) women, p=0.506. MG was associated with mucopurulent cervicitis on examination (adjusted OR=4.38, 95% CI: 1.69 to 11.33, p=0.002), but was not associated with other specific genital symptoms or signs.Conclusions: MG was as common as CT among women attending MSHC. MG was not associated with genital symptoms, but like CT, was significantly associated with cervicitis. These data provide evidence that routine testing for MG in women with common genital symptoms is not indicated. The presence of macrolide resistance in 48% of women supports use of resistance-guided therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

12. Are Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum Associated With Specific Genital Symptoms and Clinical Signs in Nonpregnant Women?

Author

Plummer, Erica L, primary, Vodstrcil, Lenka A, additional, Bodiyabadu, Kaveesha, additional, Murray, Gerald L, additional, Doyle, Michelle, additional, Latimer, Rosie L, additional, Fairley, Christopher K, additional, Payne, Matthew, additional, Chow, Eric P F, additional, Garland, Suzanne M, additional, and Bradshaw, Catriona S, additional

Published
2021
Full Text
View/download PDF

13. Evaluation of ResistancePlus MG FleXible, a ‘near-patient’ test for the detection of Mycoplasma genitalium and macrolide resistance mutations, using freshly collected clinical samples

Author

Murray, Gerald L., primary, Doyle, Michelle, additional, Bodiyabadu, Kaveesha, additional, Vodstrcil, Lenka A., additional, Garland, Suzanne M., additional, Danielewski, Jennifer, additional, Machalek, Dorothy A., additional, McGuinness, Colette, additional, Plummer, Erica L., additional, De Petra, Vesna, additional, Williamson, Deborah A., additional, and Bradshaw, Catriona S., additional

Published
2021
Full Text
View/download PDF

14. Multicenter Clinical Evaluation of a Novel Multiplex Real-Time PCR (qPCR) Assay for Detection of Fluoroquinolone Resistance in

Author

Fernández-Huerta, Miguel, Bodiyabadu, Kaveesha, Esperalba, Juliana, Bradshaw, Catriona S., Serra-Pladevall, Judit, Garland, Suzanne M., Fernandez-Naval, Candela, Jensen, Jorgen S., Pumarola Suñé, Tomàs, Ebeyan, Samantha, Lundgren, Marie, Tan, Lit Yeen, Espasa, Mateu, Murray, Gerald L., and Universitat Autònoma de Barcelona

Subjects
Antibiotic resistance, Multiplex qPCR assay, Mycoplasma genitalium, Fluoroquinolone resistance, Multicenter evaluation
Abstract

causes a common sexually transmitted infection with a marked propensity to develop antimicrobial resistance. As few treatment options exist, this poses significant challenges to clinicians. Recent diagnostic advances have resulted in tests that report the simultaneous detection of and any resistance to macrolides, the first-line treatment. This allows for therapy to be tailored to the individual, thereby optimizing treatment outcomes. causes a common sexually transmitted infection with a marked propensity to develop antimicrobial resistance. As few treatment options exist, this poses significant challenges to clinicians. Recent diagnostic advances have resulted in tests that report the simultaneous detection of and any resistance to macrolides, the first-line treatment. This allows for therapy to be tailored to the individual, thereby optimizing treatment outcomes. However, resistance to fluoroquinolones, the second-line treatment, is increasing in . In this study, we describe a new assay, MG+parC (beta), which simultaneously reports the detection of and five parC mutations that have been associated with resistance to fluoroquinolones. These mutations affect the amino acid sequence of ParC at residues S83R (A247C), S83I (G248T), D87N (G259A), D87Y (G259T), and D87H (G259C). The study tested the MG+parC (beta) assay with 202 -positive clinical samples from Australia (n = 141) and Spain (n = 61). Compared to Sanger sequencing, the assay performed with a kappa value of 0.985 (95% confidence interval [CI], 0.955 to 1.000), with a mutation detection sensitivity of 97.6% (95% CI, 87.4 to 99.9), and specificity of 100.0% (95% CI, 97.7 to 100.0). Fluoroquinolone resistance-associated mutations in parC targeted by the assay were more prevalent among the Australian cohort (23.4% [95% CI,16.3 to 31.8]) compared to the Spanish population (8.8% [95% CI, 2.9% to 19.3%]) (P = 0.019). The MG+parC (beta) kit is a simple and reliable method for simultaneous detection of and fluoroquinolone resistance-associated mutations in clinical settings. This novel diagnostic tool may extend the utility of the second line of antimicrobial therapies in infection.

Published
2019

15. Multicenter Clinical Evaluation of a Novel Multiplex Real-Time PCR (qPCR) Assay for Detection of Fluoroquinolone Resistance in Mycoplasma genitalium

Author

Fernández-Huerta, Miguel, primary, Bodiyabadu, Kaveesha, additional, Esperalba, Juliana, additional, Bradshaw, Catriona S., additional, Serra-Pladevall, Judit, additional, Garland, Suzanne M., additional, Fernández-Naval, Candela, additional, Jensen, Jorgen S., additional, Pumarola, Tomàs, additional, Ebeyan, Samantha, additional, Lundgren, Marie, additional, Tan, Lit Yeen, additional, Espasa, Mateu, additional, and Murray, Gerald L., additional

Published
2019
Full Text
View/download PDF

16. The parC mutation G248T (S83I), and concurrent gyrA mutations, are associated with moxifloxacin and sitafloxacin treatment failure for Mycoplasma genitalium

Author

Murray, Gerald L, primary, Bodiyabadu, Kaveesha, additional, Danielewski, Jennifer, additional, Garland, Suzanne M, additional, Machalek, Dorothy A, additional, Fairley, Christopher K, additional, Jensen, Jørgen S, additional, Williamson, Deborah A, additional, Tan, Lit Y, additional, Mokany, Elisa, additional, Durukan, Duygu, additional, and Bradshaw, Catriona S, additional

Published
2019
Full Text
View/download PDF

19. P606 Oh MG! the symptoms ofmycoplasma genitaliumin women

Author

Latimer, Rosie, primary, Vodstrcil, Lenka, additional, Read, Tim, additional, Doyle, Michelle, additional, Fairley, Christopher, additional, Murray, Gerald, additional, Bodiyabadu, Kaveesha, additional, Kaiser, Marti, additional, Danielewski, Jennifer, additional, Mokany, Elisa, additional, Tan, Litty, additional, Chow, Eric, additional, Garland, Suzanne, additional, and Bradshaw, Catriona, additional

Published
2019
Full Text
View/download PDF

20. Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations.

Author

Murray, Gerald L, Bodiyabadu, Kaveesha, Danielewski, Jennifer, Garland, Suzanne M, Machalek, Dorothy A, Fairley, Christopher K, Jensen, Jørgen S, Williamson, Deborah A, Tan, Lit Y, Mokany, Elisa, Durukan, Duygu, and Bradshaw, Catriona S

Subjects
*MYCOPLASMA, *MOXIFLOXACIN, *DRUG resistance in bacteria, *MYCOPLASMA pneumoniae infections, *AMINO acids, *INFECTION
Abstract

Background: The basis of fluoroquinolone treatment failure for Mycoplasma genitalium is poorly understood.Methods: To identify mutations associated with failure we sequenced key regions of the M. genitalium parC and gyrA genes for patients undergoing sequential therapy with doxycycline-moxifloxacin (201 patients, including 21 with failure) or doxycycline-sitafloxacin (126 patients, including 13 with failure).Results: The parC G248T/S83I mutation was more common among patients with failed sequential doxycycline-moxifloxacin (present in 76.2% of failures vs 7.8% cures, P < .001) or doxycycline-sitafloxacin (50% vs 16.8%, respectively; P = .01) treatment. Doxycycline-sitafloxacin was more efficacious than doxycycline-moxifloxacin against infections carrying the parC mutation conferring S83I amino acid change. Treatment was more likely to fail in these infections if they had a concurrent gyrA mutation (M95I or D99N) (P = .07 for doxycycline-moxifloxacin group and P = .009 for doxycycline-sitafloxacin group), suggesting an additive effect.Conclusions: This study indicates that parC G248T/S83I mutations contribute to failure of moxifloxacin and sitafloxacin, and the findings will inform the development of quinolone resistance assays needed to ensure optimal selection of antimicrobials for M. genitalium. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. Analysis of Infection Loads in Mycoplasma genitaliumClinical Specimens by Use of a Commercial Diagnostic Test

Author

Murray, Gerald L., Danielewski, Jennifer, Bodiyabadu, Kaveesha, Machalek, Dorothy A., Bradshaw, Catriona S., Costa, Anna-Maria, Birnie, Josh, and Garland, Suzanne M.

Abstract

Mycoplasma genitaliumis a common sexually transmitted infection with a propensity to acquire resistance to commonly used antimicrobial therapies. Bacterial load has been linked to patient symptoms and the success of treatment. In this study, we demonstrate methodology to estimate load from routine diagnostic assays using the ResistancePlus MG test (SpeeDx Pty Ltd., Australia).

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results